InvestorsHub Logo
Followers 16
Posts 1547
Boards Moderated 0
Alias Born 12/13/2009

Re: BIOChecker4 post# 443794

Friday, 12/22/2023 9:54:29 PM

Friday, December 22, 2023 9:54:29 PM

Post# of 462991

it [Missling's credibility] is the paramount issue.



Wrong--far from it. The main issue is whether Blarcamesine gets approved or not for AD and/or Rett Syndrome. The fact is Missling's credibility will become less and less of an issue as AVXL moves forward to a commercial stage company.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News